buyModerate
James D Dondero bought $1.3M of PRTK
owner at Paratek Pharmaceuticals, Inc.. 788,500 shares at an average of $1.63, traded Mar 17, 2023, filed Mar 29, 2023.
Conviction score
48Value
$1.3M
788,500 shares
Holdings after
2,156,000
+42% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +12Role10% owner
- +25Trade size$1.3M at market
- +6Relative to holdingsHoldings up 42%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- +10Track recordMedian 6-month excess return +18% over 8 past buys
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001437749-23-008428, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 17, 2023 | POpen-market purchase Common Stockindirect: See Footnote | +234,863 | $1.50 | $352k | 2,134,663 | Mar 29, 2023 |
| Mar 20, 2023 | POpen-market purchase Common Stockindirect: See Footnote | +105,137 | $1.40 | $147k | 2,239,770 | Mar 29, 2023 |
| Mar 21, 2023 | POpen-market purchase Common Stockindirect: See Footnote | +242,500 | $1.74 | $422k | 1,307,617 | Mar 29, 2023 |
| Mar 22, 2023 | POpen-market purchase Common Stockindirect: See Footnote | +106,000 | $1.77 | $188k | 2,056,000 | Mar 29, 2023 |
| Mar 23, 2023 | POpen-market purchase Common Stockindirect: See Footnote | +100,000 | $1.73 | $173k | 2,156,000 | Mar 29, 2023 |
Related signals
Other insiders at Paratek Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | Paratek Pharmaceuticals, Inc. | Michael Bigham Exec. Chairman of the Board | $31k 15,750 shares | -1% | |
| 10Weak | Paratek Pharmaceuticals, Inc. | Randall B. Brenner Chief Development & Regulatory | $9,033 4,539 shares | -1% | |
| 10Weak | Paratek Pharmaceuticals, Inc. | William M. Haskel CLO, General Counsel & Sec. | $14k 7,007 shares | -2% | |
| 26Weak | Paratek Pharmaceuticals, Inc. | Evan Loh CEO | $47k 23,489 shares | -2% | |
| 15Weak | Paratek Pharmaceuticals, Inc. | Adam Woodrow President & Chief Commercial | $13k 6,750 shares | -1% | |
| 25Weak | Paratek Pharmaceuticals, Inc. | Michael Bigham Exec. Chairman of the Board | $101k 51,375 shares | -4% | |
| 17Weak | Paratek Pharmaceuticals, Inc. | Randall B. Brenner Chief Development & Regulatory | $58k 29,282 shares | -8% | |
| 18Weak | Paratek Pharmaceuticals, Inc. | William M. Haskel CLO, General Counsel & Sec. | $75k 37,994 shares | -9% | |
| 32Weak | Paratek Pharmaceuticals, Inc. | Evan Loh CEO | $196k 99,750 shares | -8% | |
| 15Weak | Paratek Pharmaceuticals, Inc. | Adam Woodrow President & Chief Commercial | $20k 10,073 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.